| TD | tabes dorsalis; tardive dyskinesia; T-cell dependent; temporary disability; terminal device; tetanus... |
|---|---|
| TIS | tetracycline-induced steatosis; transdermal infusion system; triage illness scale; trypsin-insoluble... |
| TTS | tarsal tunnel syndrome; temporary threshold shift; through the scope; through the skin; tilt table s... |
| VF | 1) Ventricular Fibrillation ? Tx of Ventricular Fibrillation ... |
| WPW Syndrome | Wolff-Parkinson-White Syndrome ? CIx 1. Drugs; AV Conduct... |
| TTS | Transdermal Therapeutic System |
|---|---|
| L | Lidocaine |
| LID | Lidocaine |
| xylocaine | Lidocaine |
| lidocaine | Lignocaine |
oral (경구, 입의, 경구의, 구강, 구강의
| transdermal | <pharmacology> Entering through the dermis or skin, as in administration of a drug applied to the skin in ointment or patch form. (17 Mar 1998) |
|---|---|
| lidocaine | <cardiology, drug> A local anaesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. Pharmacological action: anaesthetics, local, anti-arrhythmia agents. Decreases automaticity, depresses conduction in reentrant pathways and may raise fibrillation threshold, especially in combination with bretylium. Uses: The drug of first choice for ventricular arrhythmias, ventricular ectopy, and wide complex tachycardias of unknown origin. Dose: 1-1.5 mg/kg IV bolus, followed by additional 0.5-1.5 mg/kg every 5-10 min to a total of 3 mg/kg. Can be administered via the endotracheal tube. Use 2 to 2.5 times the intravenous dose. Upon return of circulation, use continuous infusion at 2 - 4 mg/min. Reduce the maintenance dose if decreased cardiac output or hepatic failure or more than 70 years of age. Potential complications: dizziness, drowsiness, disorientation, seizures, hypotension - causes vasodilation; myocardial depression at higher concentrations; heart block - only rarely seen with high levels. Chemical name: 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide (15 Mar 2000) |
| lidocaine N-deethylase | <enzyme> Catalyzed mainly by cytochrome p-450 3a2 in rat liver microsomes Registry number: EC 1.- (26 Jun 1999) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|